10:01 AM EST, 11/11/2025 (MT Newswires) -- Sophia Genetics ( SOPH ) and Complete Genomics said Tuesday they are collaborating to expand access to precision oncology testing.

Sophia Genetics ( SOPH ) will integrate its MSK-IMPACT and MSK-ACCESS applications with sequencing technology from Complete Genomics to deliver an integrated, sample-to-report workflow for cancer genomic profiling, the companies said.

Shares of Sophia Genetics ( SOPH ) were up over 3% in recent trading.

Price: 4.45, Change: +0.10, Percent Change: +2.18